Business Context and Reporting Period
Company: Incyte Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Incyte is a drug discovery and development company focused on proprietary small molecule drugs for oncology, inflammation, and diabetes. The company has no commercial product sales and relies on licensing revenues and capital markets to fund operations.
Key Financial Metrics
| Metric (in thousands) | Q3 2009 | Q3 2008 | YTD 9M 2009 | YTD 9M 2008 |
|---|---|---|---|---|
| Total Revenues | $939 | $1,061 | $2,399 | $2,981 |
| Net Loss | $(43,357) | $(44,794) | $(123,428) | $(130,515) |
| Diluted Loss Per Share | $(0.44) | $(0.48) | $(1.26) | $(1.50) |
| Cash & Cash Equivalents | $367,478 | $178,767 | $367,478 | $108,854 |
| Total Debt (Principal) | $635,551 | $396,167 | $635,551 | $396,167 |
| Operating Cash Flow (9M) | $(106,227) | $(108,648) | $(106,227) | $(108,648) |
Note: Debt figures represent aggregate principal amounts outstanding as of September 30, 2009, including $400M in new 4.75% Senior Notes.
Material Changes vs. Prior Period
- Capital Raising: In September 2009, Incyte completed a public offering of 20.7 million shares for net proceeds of $132.7 million and a private placement of $400 million in 4.75% Convertible Senior Notes (net proceeds $388.0 million).
- Debt Repurchases: The company repurchased $86.3 million of 3 9/16% Senior Notes and $99.0 million of 3 9/16% Subordinated Notes, resulting in a $5.4 million loss on debt repurchases.
- Liquidity Improvement: Cash and cash equivalents increased from $178.8 million at year-end 2008 to $367.5 million at September 30, 2009, driven by financing activities.
- Expense Reduction: Research and Development (R&D) expenses decreased by 28% in Q3 2009 compared to Q3 2008 ($26.5M vs $36.9M) due to pipeline prioritization. Selling, General, and Administrative (SG&A) expenses increased slightly due to headcount growth for commercial preparations.
- Derivative Liability: A new $148.1 million embedded derivative liability was recorded related to the conversion feature of the new 4.75% Senior Notes due to insufficient authorized common shares.
Guidance, Outlook, and Risks
- Outlook: Management anticipates incurring additional losses for several years. The company expects to fund operations for at least the next 12 months with current cash and marketable securities ($395.2 million available).
- Stockholder Meeting: A special meeting is scheduled for November 24, 2009, to approve an increase in authorized common stock. This is critical to avoid penalty interest rates on the 4.75% Senior Notes.
- Contingent Interest Risk: If sufficient common shares are not reserved by January 1, 2010, the interest rate on the 4.75% Senior Notes will increase to 10%. If not resolved by June 30, 2010, the rate will rise to 15%, increasing by 5% annually thereafter.
- Derivative Accounting: Until the share reserve issue is resolved, the conversion feature of the new notes is treated as a liability, subject to quarterly revaluation through earnings.
- Operational Focus: The company is prioritizing the JAK inhibitor program (INCB18424) for myelofibrosis and psoriasis. Other programs (c-MET, IDO) are paused pending additional funding or partnerships.
Investor Verification Checklist
- Share Reserve Approval: Verify the outcome of the November 24, 2009, stockholder meeting regarding the increase in authorized shares to prevent penalty interest rates.
- Derivative Liability Volatility: Monitor quarterly revaluation of the $148.1 million embedded derivative liability, which impacts net income.
- Cash Burn Rate: Assess the sustainability of the $106 million operating cash burn over the next 12 months against the $395 million liquidity position.
- Debt Maturity: Review the status of $215.6 million in convertible notes maturing in February 2011 and the company's ability to refinance or repurchase them.
- Clinical Progress: Track Phase III trial results for INCB18424 (myelofibrosis) as the primary driver for future commercialization and potential profitability.